Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X. Zhu, Yvonne H. Sada, Richard S. Finn et al.|The Lancet Oncology|2018Cited by 2.5k
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Yabing Guo, Jeong Heo et al.|The Lancet|2023Cited by 514
KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.Andrew X. Zhu, Masatoshi Kudo, Richard S. Finn et al.|Journal of Clinical Oncology|2018Cited by 37
Preoperative gemcitabine-nab-paclitaxel (G-NP) for (borderline) resectable (BLR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC): Feasibility results and early response monitoring by Diffusion-Weighted (DW) MR.Jean‐Luc Van Laethem, Raphaël Maréchal, Maria Antonietta Bali et al.|Journal of Clinical Oncology|2016Cited by 12
Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.Andrew X. Zhu, Masatoshi Kudo, Richard S. Finn et al.|Journal of Clinical Oncology|2018Cited by 11